HeartSciences Inc. (HSCSW)
| Market Cap | 10.76M +186.1% |
| Revenue (ttm) | 4,319 -76.6% |
| Net Income | -9.14M |
| EPS | -3.48 |
| Shares Out | 3.90M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8 |
| Open | 0.0545 |
| Previous Close | n/a |
| Day's Range | 0.0545 - 0.0562 |
| 52-Week Range | 0.0349 - 0.1700 |
| Beta | 1.80 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 10, 2026 |
About HSCSW
HeartSciences Inc., a medical technology company, focuses on advancing electrocardiography (ECG) through the integration of artificial intelligence. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-native vendor- and device-agnostic EC... [Read more]
News
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on August 24, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on August 21, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on August 20, 2026, providing details for shareholder voting and corporate governance matters.
Fortitude Mining purchases 411,522 shares of HeartSciences in private placement
HeartSciences (HSCS) announced Fortitude Mining purchased 411,522 shares of HeartSciences’ common stock for an aggregate purchase price of approximately $1M in a private placement. The shares were iss...
Fortitude Invests $1.0 Million in HeartSciences at a 22% Premium with No Adjustment to the Merger Consideration
Fortitude purchased approximately $1,000,000 of HeartSciences' shares of common stock at $2.43 per share, a 22% premium to the closing price on the purchase date The exchange ratio under the merger ag...
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on August 19, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on August 19, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on August 18, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on August 7, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on August 6, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on August 4, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on July 30, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Files Preliminary Proxy Statement for Business Combination with Fortitude Mining Holdings; Provides Business Update and Reports Fiscal 2026 Financial Results
Company believes proposed Fortitude Mining Holdings business combination represents a significant value creation opportunity for the Company's shareholders Fiscal 2026 saw the full commercial launch o...
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on July 29, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on July 29, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on July 28, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on July 28, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on July 27, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on July 27, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on July 27, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Files Its Fiscal 2026 Annual Report on Form 10-K
Company believes proposed Fortitude merger represents a significant opportunity for the Company's shareholders; preliminary proxy statement in connection with the Proposed Transaction expected to be f...
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on July 23, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Annual report: Q4 2026
HeartSciences has published its Q4 2026 annual report on July 23, 2026.
HeartSciences Earnings release: Q4 2026
HeartSciences released its Q4 2026 earnings on July 23, 2026, summarizing the period's financial results.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on July 22, 2026, providing details for shareholder voting and corporate governance matters.